Longitudinal stability of resting-state networks in normal aging, mild cognitive impairment, and Alzheimer's disease.

Test–retest reliability is essential for using resting-state functional magnetic resonance imaging (rs-fMRI) as a potential biomarker for Alzheimer's disease (AD), especially when monitoring longitudinal changes and treatment effects. In addition, test–retest variability itself might represent a feature of AD. Using 3.0 T rs-fMRI data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, we examined the long-term (1-year) test–retest reliability of resting-state networks (RSNs) in 31 healthy elderly subjects, 63 patients with mild cognitive impairment (MCI), and 17 patients with AD by applying temporal concatenation group independent component analysis and dual regression. The intraclass correlation coefficient estimates of RSN amplitudes ranged from 0.44 to 0.77 in healthy elderly subjects, from 0.31 to 0.62 in patients with MCI, and from −0.06 to 0.44 in patients with AD. The overall test–retest reliability of RSNs was lower in patients with MCI than in healthy elderly subjects, and was lower in patients with AD than in patients with MCI. The differences in the test–retest reliabilities were due to the RSN amplitudes rather than the RSN shapes. Head motion was not significantly different among the three groups of subjects. The results indicate that the test–retest stability of RSNs generally declines with progression to MCI and AD, mainly due to the RSN amplitudes rather than the RSN shapes. The test–retest instability in MCI and AD may reflect progressive neurofunctional alterations related to the pathology of AD. • Test–retest reliability of resting-state networks (RSNs) in MCI and AD is unclear. • Test–retest RSN stability usually declines with progression to MCI and AD. • Test–retest instability is mainly due to RSN amplitudes rather than RSN shapes. • Test–retest instability may reflect neurofunctional alterations due to AD. [ABSTRACT FROM AUTHOR]